|
[1]American Cancer Society.Cancer facts and figures 2015[Z].USA:American Cancer Society(ACS):Atlanta,2015.
|
|
[2]MAMON HJ,NIEDZWIECKI D,HOLLIS DA,et al.Phase 2 trial of gemcitabine,5-florouracil,and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma:Cancer and Leukemia Group B(CALGB)80003[J].Cancer,2011,117(12):2620-2628.
|
|
[3]KLEEFF J,KORC M,APTE M,et al.Pancreatic cancer[J].Nat Rev Dis Primers,2016.[Epub ahead of print].
|
|
[4]KARANDISH F,MALLIK S.Biomarkers and targeted therapy in pancreatic cancer[J].Biomark Cancer,2016.[Epub ahead of print].
|
|
[5]GOPINATHAN A,MORTON JP,JODRELL DI,et al.GEMMs as preclinical models for testing pancreatic cancer therapies[J].Dis Model Mech,2015,8(10):1185-1200.
|
|
[6]LEE S,HEINRICH E,LU J,et al.Epidermal growth factor receptor signaling to the mitogen activated protein kinase pathway bypasses ras in pancreatic cancer cells[J].Pancreas,2016,45(2):286-292.
|
|
[7]BOURNET B,MUSCARI F,BUSCAIL C,et al.KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma[J].Clin Transl Gastroenterol,2016.[Epub ahead of print].
|
|
[8]DING N,CUI XX,GAO Z,et al.A triple combination of atorvastatin,celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors[J].Int J Oncol,2014,44(6):2139-2145.
|
|
[9]MUSCARELLA P,WILFONG LS,ROSS SB,et al.A randomized,placebo controlled,double blind,multicenter phase 2 adjuvant trial of the efficacy,immunogeneicity,and safety of GI-4000 plus Gem vs.Gem alone in patients with resected pancreas cancer with activating Ras mutations/survival and immunology analysis of the R1 Subgroup[J].J Clin Oncol,2012,30:e14501.
|
|
[10]WANG JP,WU CY,YEH YC,et al.Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations:a randomized,open-label,prospective trial[J].Oncotarget,2015,6(20):18162-18173.
|
|
[11]LEE CC,SHIAO HY,WANG WC,et al.Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer[J].Expert Opin Investig Drugs,2014,23(10):1333-1348.
|
|
[12]PHILIP PA,BENEDETTI J,CORLESS CL,et al.PhaseⅢstudy comparing gemcitabine plus cetuximab vs.gemcitabine in patients with advanced pancreatic adenocarcinoma:Southwest oncology group—directed intergroup trial S0205[J].J Clin Oncol,2010,28(22):3605-3610.
|
|
[13]MOORE M,GOLDSTEIN D,HAMM J,et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phaseⅢtrial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,2007,25(15):1960-1966.
|
|
[14]NAMKUNG J,KWON W,CHOI Y,et al.Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value[J].J Gastroenterol Hepatol,2015.[Epub ahead of print].
|
|
[15]EL-RAYES BF,ZALIPSKI MM,SHIELDS AF,et al.A phaseⅡstudy of celecoxib,gemcitabine,and cisplatin in advanced pancreatic cancer[J].Investig New Drugs,2005,23(6):583-590.
|
|
[16]MUKHERJEE P,BASU GD,TINDER TL,et al.Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition[J].J Immunol,2009,182(1):216-224.
|
|
[17]RAO CV,JANAKIRAM NB,MADKA V,et al.Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma[J].Oncotarget,2015,6(32):33290-33305.
|
|
[18]MOHAMMED A,JANAKIRAM NB,MADKA V,et al.Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression[J].Oncotarget,2015,6(17):15524-15539.
|
|
[19]MOORE MJ,HAMM J,DANCEY J,et al.Comparison of gemcitabine vesus the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced or adenocarcinoma of the pancreas:a phaseⅢtrial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,2003,21(2):3296-3300.
|
|
[20]TAI CJ,HUANG MT,WU CH,et al.Combination of two targeted medications(bevacizumab plus cetuximab)improve the therapeutic response of pancreatic carcinoma[J].Medicine(Baltimore),2016.[Epub ahead of print].
|
|
[21]YU Z,ZHONG W,TAN ZM,et al.Gemcitabine adjuvant therapy for resected pancreatic cancer:a meta-analysis[J].Am J Clin Oncol,2015,38(3):322-325.
|
|
[22]RENI M,CEREDA S,MILELLA M,et al.Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma:a phaseⅡrandomised trial[J].Eur J Cancer,2013,49(17):3609-3615.
|
DownLoad: